• Who we are
Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
  • CD28 targeting
  • How it works

Contact

NovImmune SA
15 Chemin du Pré-Fleuri
1228 Plan-les-Ouates

Phone: +41 22 552 72 00
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

UID: CHE-104.261.899

Terms of Use

NovImmune SA owns the copyright for the entire website. Content may not be used and copied in any other context. All liability claims for any information contained on this website are excluded. Logos and images may vary. Copying, using and modifying the contents of the website, even in part, requires the written consent of NovImmune SA.

Web

iage AG
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: www.iage.ch

iage

klimafreundlich.ch

The Environmental Label klimafreundlich.ch has the environmentally responsible use of our resources and serves as a sign of ecological thought and action. www.klimafreundlich.ch

klimafreundlich gehostet

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body


Read more

LinkedIn